Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Investor Day (May 2024)
109 slides from Indivior Pharmaceuticals's investor day presentation, May 23, 2024
Slide 1: Transforming Lives & Driving Value Creation
Transforming Lives & Driving Value Creation May 23, 2024
Slide 2: Forward-looking Statements
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding strategic priorities, strategies f
Slide 3: Today's Speakers
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Today’s Speakers Mark Crossley Richard Simkin Christian Heidbreder, Ph.D. Jeff Burris Ryan Preblick CHIEF EXECUTIVE OFFICER CHIEF COMMERCIAL OFFICER CHIEF SCIENTIFIC OFFICER CHIEF LEGAL OFFICER CHIEF FINANCIAL
Slide 4: Our Company & Strategy
Our Company & Strategy Mark Crossley CHIEF EXECUTIVE OFFICER
Slide 5: Context for Today's Session
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Context for Today’s Session Introduce Indivior ahead Outline clear strategic Demonstrate our of the U.S. primary listing priorities to create confidence in our future durable shareholder value 5
Slide 6: Agenda
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Agenda 1 Our Company & Strategy 4 Summary of Ongoing Litigation Mark Crossley, CEO Jeff Burris, CLO 2 Delivering on the Potential of our Products 5 Operational Excellence Richard Simkin, CCO Ryan Preblick, CFO
Slide 7: Why Indivior?
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Why Indivior? Global leader Strong track Clear strategic Scalable model to in addiction record of priorities to deliver attractive treatment with execution and create durable earnings and cash tremendous de-ris
Slide 8: An Unwavering Focus on Patients Drives Our Business
Annual Report and Accounts 2022 T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E CR E A T ION | MA Y 23, 2024 Many journeys, one destination An Unwavering Focus on Patients Drives our Business Together We’re Working To Change Lives Annual Report 2017 8
Slide 9: Addiction is a Global Crisis
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Addiction is a Global Crisis Opioids Cannabis Alcohol Amphetamines 60m people use opioids 219m users >100m people with & Cocaine for non-medical purposes Alcohol Use Disorder 58m users UNODC, World Drug Report
Slide 10: Addiction and Substance Abuse are Fueling a Major Health Crisis
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Addiction and Substance Abuse are Fueling a Major Health Crisis April 11, 2024 November 8, 2023 October 26, 2023 D.C. Opioid Overdose Deaths Surge The Global Network Behind the The Cannabis That People Are Usin
Slide 11: Indivior is a Global Leader in Addiction Treatment
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Indivior is a Global Leader in Addiction Treatment Net Revenue by Geography Net Revenue by Product TTM1 (through Q1 2024) TTM1 (through Q1 2024) $XXXm $356m 4% CASH2 &CASH INVESTMENTS 16% 24% $1,124m ~XXX 1,100
Slide 12: Clear Strategic Priorities to Drive Value Creation
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Clear Strategic Priorities to Drive Value Creation Grow SUBLOCADE >$1.5Bn Diversify Revenue ➔ FY 2023 SUBLOCADE® NR +54% YoY ➔ Acquisition and integration of Opiant ➔ 136,900* SUBLOCADE patients at FY 2023 (+66
Slide 13: Confident in Medium-term Performance Goals
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Confident in Medium-term Performance Goals – Double-Digit % NR CAGR & Margin Expansion Total Net Revenue Key Top-line Drivers: (U.S.$) • SUBLOCADE >$1.5 bn potential annual NR FY 24 – expected to reach $1 bn NR
Slide 14: Delivering on Our Profitable Growth Thesis
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Delivering on Our Profitable Growth Thesis ($ in mil.) Total Net Revenue (NR) SUBLOCADE NR PERSERIS NR Operating Profit $1,285 $850 $355 Reported $1,093 Adjusted1 $630 $269 $903 $60 $791 $212 $213 $187 $647 $40
Slide 15: What You Will Come Away With Today
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 What You Will Come Away With Today: Passion for Patients, Visible Growth, Pioneering Science, and a Scalable Business Model We are a global leader in SUBLOCADE is a transformational addiction treatment asset wi
Slide 16: Delivering on the Potential of our Products
Delivering on the Potential of our Products Richard Simkin CHIEF COMMERCIAL OFFICER
Slide 17: Our Commercialized and Proprietary Treatments
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Our Commercialized and Proprietary Treatments Treatment Indication Peak NR1 Goal IP2 Protection Long-acting injectable (LAI) for >$1.5 bn 12 Orange Book patents moderate to severe opioid use (2031 – 2038) disor
Slide 18: SUBLOCADE
SUBLOCADE® UNLOCKING >$1.5 BN POTENTIAL ANNUAL NR OPPORTUNITY
Slide 19: Indivior is a Global Leader in Addiction
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Indivior is a Global Leader in Addiction Strengthening our position Continuing to expand our Unique product pipeline expected in the U.S. behind SUBLOCADE footprint across Rest of World to address broader addic
Slide 20: The U.S. is our Highest Value at Stake Market
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 The U.S. is our Highest Value at Stake Market North America Has the Highest Prevalence of U.S. Opioid Misuse in the World1 - % of adult population - 4% 3.37 2.44 U.S. Market Dynamics: 2.29 1.76 • Liberal prescr
Slide 21: Positive Structural Dynamics and Underlying Growth Trends Expected to Expand BMAT
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Positive Structural Dynamics and Underlying Growth Trends Expected to Expand BMAT 1 Indiv ior internal research and analy sis 21
Slide 22: A Significant Treatment Gap Exists in the U.S.
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 A Significant Treatment Gap Exists in the U.S. Range of Estimates Across Key Patient Metrics 4.0m1 8.9m2 12.0m3 Misuse opioids in U.S. (Total Addressable Ma rket) 2.7m4 3.1m2 6.1m2 OUD diagnosed in U.S. (Servi
Slide 23: Enabling U.S. Treatment Backdrop
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Enabling U.S. Treatment Backdrop DATA 2000 requirement removed December 2022 15 U.S. states offering comprehensive MAT in jails and prisons 1 Telehealth expansion begun during pandemic continues to be extended
Slide 24: Overdose Crisis is Being Driven by Synthetics
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Overdose Crisis is Being Driven by Synthetics: ~75,000 per Annum 25 Other Synthetic Opioids Leading 20 (Fentanyl) – Prescribed or Illicitly Manufactured) Cause of Death Deaths per 100,000 15 in adults aged 18-4
Slide 25: Evolving Treatment Considerations with the Synthetic Opioid Crisis
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Evolving Treatment Considerations with the Synthetic Opioid Crisis Goals Before Considerations Today ▪ Abstinence the top priority (treat relapse) ▪ Reduce relapse rate, extend recovery ▪ MOUD with buprenorphin
Slide 26: SUBLOCADE Meets the Challenge of Today's Opioid Crisis
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 SUBLOCADE®1 Meets the Challenge of Today’s Opioid Crisis SUPPRESS REDUCE EXTEND the high illicit opioid use effect vs. higher- potency opioids3 • No daily fluctuations • Backed by robust • Blocks high in most p
Slide 27: SUBLOCADE is Helping Reshape Patients' Lives
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 SUBLOCADE is Helping Reshape Patients’ Lives SUBLOCADE® Total Patients1 (in Thousands) Initially 136.9 Targeting 82.5 270,000 49.0 Patients 28.9 13.7 4.7 2018 2019 2020 2021 2022 2023 1 On a rolling 12 mos. bas
Slide 28: Proven Growth Strategy to Support >$1.5 bn NR Potential
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Proven Growth Strategy to Support >$1.5 bn NR Potential 1. 2. 3. Accelerate Adoption in Expand Access to Proven Go-To Market Organized Health Treatment in the Criminal Model Systems (OHS) Justice System (CJS) 2
Slide 29: OHS and CJS Provide Care for the Majority of OUD Patients
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 OHS and CJS Provide Care for the Majority of OUD Patients Integrated Delivery Federal Health Key Criminal Justice Independent Networks Systems Accounts System Practices ~3.0m+ ~1.2m Patients 2 ~160k Patients 2
Slide 30: Continued Strong Momentum in OHS and CJS Segments
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Continued Strong Momentum in OHS and CJS Segments Levers of Depth Key Metrics (at FY 2023) OHS 1. Activate OHS Facilities ➔ ~4.8K OHS active facilities (+37% vs. 2022) • >15k facilities 2. Expand OHS HCPs Adopt
Slide 31: U.S. Expansion in Place — ASOC, CJS, Medical
TRANSFO R M I N G LIVES & DRIVIN G VALU E CREAT IO N | MAY 23, 2024 U.S. Expansion in Place —ASOC1, CJS, Medical Increased Field U.S. Counties with One or More Alternative Sites of Care Capabilities (~1,160 ASOCs across 21 states) +50% Sales Force (OHS-affiliated & Indep. HCPs) +25% CJS Team (Federa
Slide 32: SUBLOCADE: Confident in Delivering >$1.5 bn NR Target
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 SUBLOCADE: Confident in Delivering >$1.5 bn NR Target 8.9m 3.1m ~270,000 Misuse opioids in U.S. 1 OUD diagnosed in U.S. 1 Target SUBLOCADE patients • ~20% treatment rate2 Undertreated Disease & • Increasing acc
Slide 33: OPVEE
OPVEE® UNIQUELY POSITIONED TO HELP COMBAT TODAY’S OPIOID EPIDEMIC
Slide 34: Synthetic Opioids are Public Enemy No. 1
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Synthetic Opioids are Public Enemy No. 1 & Pervasive in the Illicit Drug Supply The 4th Wave of Overdose Crisis1 Fentanyl (no stimulants) Fentanyl (w/ stimulants) U.S. Authorities Seized >115m Illicit Pills Con
Slide 35: Synthetic Opioids are Challenging Current Treatment Options
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Synthetic Opioids are Challenging Current Treatment Options National Institute Multiple sequential Naloxone half-life on Drug Abuse doses of naloxone shorter than all “Most of the crews leadership called necess
Slide 36: OPVEE Squarely Addresses the Current Wave of Synthetic Opioid Overdoses
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 OPVEE Squarely Addresses the Current Wave of Synthetic Opioid Overdoses Triple Threat of Synthetic Opioid Rapid Potent Long-Lasting Pharmacology such as Fentanyl . Key treatment attributes: • Rapid absorption a
Slide 37: Combination of Top Down and Bottom Up Approach is Required
TRANSF OR M IN G LIVES & DRIVING VALUE CREATI ON | MAY 23, 2024 Combination of Top Down (State-Level) and Bottom Up (First-Line Users) Approach is Required Standing Orders: Existing Opioid Overdose Reversal Markets • 31 states’ standing orders include OPVEE or are entity-specific. Recent • Single st
Slide 38: Case Study: Oakland County OPVEE Pilot Program
TRANS FO R MI N G LI VES & DRI VI NG VALU E CREATI O N | MAY 2 3 , 2 0 2 4 CASE STUDY: OAKLAND COUNTY OPVEE PI LOT PROGRAM 1 2 3 4 Oakland County, MI OPVEE Pilot Program ▪ Partnership between Alliance of Coalitions for Healthy Communities, and Oakland County Sheriff Dept Funding: Utilized funds Stan
Slide 39: OPVEE BARDA Contract
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 OPVEE BARDA1 Contract ◆ Executed in 2023 ◆ Worth up to $110m2 ◆ 10-year contract ◆ Technical and handling standards being met ◆ First product delivery (~$8m) expected in Q3 2024 1 BARDA: Biomedical Adv anced Re
Slide 40: Confident in Delivering $150m to $250m Peak NR Goal for OPVEE
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Confident in Delivering $150m to $250m Peak NR Goal for OPVEE Differentiated product Expansive experience Highly experienced targeting synthetic program expected to lead commercial team (fentanyl) overdose cris
Slide 41: PERSERIS
PERSERIS® SIGNIFICANT OPPORTUNITY TO DIFFERENTIATE IN SCHIZOPHRENIA
Slide 42: Schizophrenia is a Lifelong Disease Marked by Periods of Stability and Decompensation
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Schizophrenia is a Lifelong Disease Marked by Periods of Stability and Decompensation Clear advantage to a product that can achieve clinically relevant levels on day one Mi l d Symptoms , Level of Functioning1
Slide 43: Schizophrenia Patient Funnel
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Schizophrenia Patient Funnel Patients with 2,800,000 1 Schizophrenia 2,800,000 Continued Patients in 1,700,000 2,300,000 1 significant Treatment opportunity for LAI penetration Patients 500K 2 300k on LAIs 1 ww
Slide 44: U.S. LAI Antipsychotic Market Growth is being Fueled by New Products
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 U.S. LAI Antipsychotic Market Growth is being Fueled by New Products and Patients Moving to LAIs LAIs currently make up ~17% of the overall schizophrenia antipsychotic market Net Rev. Risvan® ($ in mil.) UZEDY®
Slide 45: LAI Market is Divided – Risperidone / Paliperidone & Aripiprazole
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 LAI Market is Divided – Risperidone / Paliperidone & Aripiprazole Antipsychotic LAI Market1 • 1-month LAIs Risperidone/Paliperidone Patient Aripiprazole Patient the preferred (67% of LAI Rx) (33% of LAI Rx) dos
Slide 46: PERSERIS — Differentiation is Clear and Understandable
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 PERSERIS1 — Differentiation is Clear and Understandable PERSERIS Differentiated Profile $80 PERSERIS Net Revenue • First approved subcutaneous risperidone LAI $55m to $65m2 $60 • 4 to 6 hours peak plasma concen
Slide 47: PERSERIS is Gaining Stronger Advocacy and Driving Depth in Prescription Volume
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 PERSERIS is Gaining Stronger Advocacy and Driving Depth in Prescription Volume LAI market driven by large PERSERIS capturing disproportionate percentage of new-to-brand Rx1 share of NBRx 12-month 12-month Total
Slide 48: Confident in Delivering $200m to $300m Peak NR Goal for PERSERIS
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Confident in Delivering $200m to $300m Peak NR Goal for PERSERIS Building Blocks to $200m – $300m Potential Annual NR 1. Attractive, dynamic, growing market HCPs Writing Rx per HCP (annual) 6,000 5,500 40 36 4,
Slide 49: Pioneering R&D for Patients
Pioneering R&D for Patients Christian Heidbreder, Ph.D. CHIEF SCIENTIFIC OFFICER
Slide 50: Today's R&D Agenda
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Today’s R&D Agenda 1 R&D, Medical Affairs & Safety Organization 4 Cannabis Use Disorder (CUD) 2 Opioid Use Disorder (OUD) 5 Alcohol Use Disorder (AUD) 3 Opioid Overdose Rescue (ORS) 6 Conclusion
Slide 51: R&D, Medical Affairs & Safety Organization
R&D, Medical Affairs & Safety Organization
Slide 52: A Dedicated & Experienced Team Globally
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 A Dedicated & Experienced Team Globally Main Hubs in Richmond, VA and Fort Collins, CO (U.S.); Hull, Slough and London (U.K.) Frank Gray (51) SVP Global Medicines Dev elopment Clinical development & operations;
Slide 53: Longstanding Innovation Leadership In The Treatment Of Opioid Use Disorder
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Longstanding Innovation Leadership In The Treatment Of Opioid Use Disorder… Discovery and first synthesis of buprenorphine at the Reckitt & Colman (R&C) labs based in Kingston upon Hull, UK 1966 Source: Heidbre
Slide 54: … with Strategic Focus & Vision …
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 … with Strategic Focus & Vision … MILLION DRUG USERS IN 2021 (5.8 % OF THE GLOBAL POPULATION AGED 15–64) OPIOIDS: 60 million people used opioids for OUR VISION: non-medical purposes in 2021. Most lethal group a
Slide 55: … and A Growing Pipeline
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 … and A Growing Pipeline REGULATORY COMMERCIAL BRAND/PRODUCT NAME PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL LAUNCH SUBLOCADE® (Opioid Use Disorder) (buprenorphine extended-release) injection for subcutaneous
Slide 56: Opioid Use Disorder
Opioid Use Disorder SE INDIVIOR
Slide 57: SUBLOCADE
SUBLOCADE” SE INDIVIOR
Slide 58: Scientific Foundation of SUBLOCADE: Plasma Concentrations and Receptor Occupancy
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Scientific Foundation of SUBLOCADE: Relationship Between Plasma Concentrations of Buprenorphine, Brain μ-opioid Receptor Occupancy & Clinical Efficacy 2 ng/mL 100 µORO (%) or probability (%) Buprenorphine plasm
Slide 59: Probability of Fentanyl-Induced Respiratory Depression Decreases With Buprenorphine >2 ng/mL
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 The Probability of Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Subjects Decreases With Plasma Concentrations of Buprenorphine >2 ng/mL → At buprenorphine plasma concentrations of 1 ng/mL, bupreno
Slide 60: Rapid Induction with SUBLOCADE in Patients Using Synthetic Opioids is Feasible
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Rapid Induction with SUBLOCADE Treatment in Patients Using Synthetic Opioids is Feasible Clinical Opioid Withdrawal Scale (COWS) scores by fentanyl use status subgroup. Mean COWS scores <5 (no active withdrawal
Slide 61: SUBLOCADE May Lower Rates of Non-fatal Overdose Events
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 SUBLOCADE Treatment May Lower Rates of Reported Non-fatal Overdose Events vs. Daily Sublingual Buprenorphine And Methadone 20 18 18 16 14 12 10.7 10 10 Source: Lee K, Zhao Y, Merali T, Fraser C, Kozicky JM, Mor
Slide 62: SUBLOCADE Leads to Fewer In-jail Clinic Visits and Increased Retention
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 SUBLOCADE Treatment Leads to Fewer In-jail Clinic Visits and Increased Community Buprenorphine Treatment Retention vs. Standard Daily Sublingual Buprenorphine SUBLOCADE % SLB % 80 69.2 70 60 57 Source: Lee JD e
Slide 63: Longer SUBLOCADE Treatment, Higher Likelihood of Abstinence
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 The Longer the SUBLOCADE Treatment Duration, the Higher the Likelihood of Continuous Self-Reported Abstinence 12 Months after Treatment Cessation 80% 70% 75.0% % Abstinent subjects 60% 50% Source: Ling W, Nadip
Slide 64: SUBLOCADE: 2024 R&D and Medical Affairs & Safety Objectives
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 SUBLOCADE: 2024 R&D and Medical Affairs & Safety Objectives Label updates Evidence Product Access expansion Generation & optimization Publications Label Submissions Evidence generation: Phase 4 Oxygen absorber
Slide 65: INDV-6001 (3-Month Long-Acting Injectable Buprenorphine)
INDV-6001 (3-Month Long-Acting Injectable Buprenorphine)
Slide 66: INDV-6001 (3-Month Long-acting Injectable Buprenorphine)
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 INDV-60011 (3-Month Long-acting Injectable Buprenorphine) ▪ October 11, 2023: Acquisition of the exclusive global rights to develop, manufacture, and commercialize Simulation of transition from SUBLOCADE (300/1
Slide 67: INDV-2000 (Selective Orexin-1 Receptor Antagonist)
INDV-2000 (Selective Orexin-1 Receptor Antagonist)
Slide 68: INDV-2000 is a Potent and Selective OX1R Antagonist in Phase 2
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 INDV-2000 is a Potent and Selective OX1R Antagonist Currently in a Clinical Phase 2 Proof of Concept Study ▪ $10.6M NIH HEAL (Helping to End Addiction Long-term) initiative grant (1UG3DA050308-01) in 2019 ▪ Suc
Slide 69: Opioid Overdose Rescue
Opioid Overdose Rescue SE INDIVIOR
Slide 70: Fentanyl Use Continues to Rise across the U.S.
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Fentanyl Use Continues to Rise across the U.S. Lethal quantities of heroin (left), fentanyl (middle) and carfentanil (right). Carfentanil is roughly 100 times more potent than fentanyl, which itself is about 50
Slide 71: OPVEE – Key 2024+ Objectives
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 OPVEE – Key 2024+ Objectives Biomedical Advanced Research and Development Authority (BARDA) alliance Initiation of Post Marketing Requirements (PMRs): pediatric and dodecylmaltoside (DDM) studies Product optimi
Slide 72: Differentiated PD Profile of OPVEE vs. Intranasal Naloxone
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Differentiated Pharmacodynamic (PD) Profile of OPVEE vs. Intranasal Naloxone Objective: Open-label, randomized, crossover study in healthy volunteers comparing the reversal of remifentanil-induced respiratory d
Slide 73: Model of Synthetic Opioid Overdose Reversal
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Model of Synthetic Opioid Overdose Reversal FDA model implemented 1 Results with IM naloxone were successfully reproduced Model expanded with IN nalmefene and IN naloxone 2 data (PK and binding parameters) Mode
Slide 74: Model of Synthetic Opioid Overdose Reversal by OPVEE vs. Intranasal Naloxone
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Model of Synthetic Opioid Overdose Reversal by OPVEE vs. Intranasal Naloxone Objective: Compare cardiac arrest events caused by synthetic opioids (fentanyl, carfentanil) following rescue by intranasal (IN) admi
Slide 75: Cannabis Use Disorder
Cannabis Use Disorder SE INDIVIOR
Slide 76: Cannabis Use has Become more Prevalent over the Past Decade
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Cannabis Use has Become more Prevalent over the Past Decade Prevalence >12 year – 2023 Prevalence 15-64 year – 2023 61.9 million last year users 22.6 million last year users Source: https://www.ncsl.org/civil-a
Slide 77: The Negative Health Effects of Chronic Cannabis Use are Becoming Clearer
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 The Negative Health Effects of Chronic Cannabis Use are Becoming Clearer A quadruple confluence of factors is leading to increasing CUD diagnoses: • Growing prevalence of use • Increasing intensity of use (freq
Slide 78: CB1 Receptor Stimulation by THC Increases Brain Pregnenolone
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 CB1 Receptor Stimulation by THC Increases Brain Pregnenolone AEF0117 Is the First Synthetic CB1 Signaling-specific Negative Allosteric Modulator Breakthrough science Challenge Solution: AEF0117 By binding a spe
Slide 79: AEF0117 Reduces the Subjective Effects of Cannabis
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 AEF0117 Reduces the Subjective Effects of Cannabis & Cannabis Self-administration Intoxication subscale Strength of Cannabis (CSR) 80 90 70 80 VAS Score VAS Score 60 70 50 60 40 50 30 40 20 40 60 90 105 20 40 6
Slide 80: AEF0117: Development Roadmap
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 AEF0117: Development Roadmap Design: Phase 2B, randomized, double-blind, placebo-controlled, 4- Promising clinical Phase 1 and Phase 2A safety, arm, parallel-group, prospective, tolerability, and efficacy multi
Slide 81: Alcohol Use Disorder
Alcohol Use Disorder SE INDIVIOR
Slide 82: 108m People Worldwide with Alcohol Use Disorder
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 108m People Worldwide with Alcohol Use Disorder (AUD) 29.5m Past-year AUD Diagnosed in U.S. 29.5M past-year AUD diagnosed in U.S. Only 2.1% (or 634,000 people) received MAT in the past year Source: Global Burde
Slide 83: INDV-1000 (GABA-b Positive Allosteric Modulator) Development
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 INDV-1000 (GABA-b Positive Allosteric Modulator) Development From lead optimization to candidate selection • Selection of two lead compounds for comprehensive in vitro and in vivo characterization. • Formulatio
Slide 84: Conclusion
Conclusion SE INDIVIOR
Slide 85: Indivior's vision is to pioneer addiction medicine
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Indivior’s vision is to pioneer addiction medicine and build competitive advantages with • A unique portfolio of assets to address unmet medical needs in people with substance use disorders (SUD) • A compelling
Slide 86: Summary of Ongoing Litigation
Summary of Ongoing Litigation Jeff Burris CHIEF LEGAL OFFICER
Slide 87: Certain Legal Matters
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Certain Legal Matters Antitrust Litigation Civil Opioid UK Shareholder Dental Multi-District and Consumer Litigation Claims Litigation (MDL) Protection 87
Slide 88: Operational Excellence
Operational Excellence Ryan Preblick CHIEF FINANCIAL OFFICER
Slide 89: Key Takeaways
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Key Takeaways Attractive Growth Scalable Business Strategic Priorities Strong Cash Profile Model Well Funded Generation Allows Balanced Capital Allocation 89
Slide 90: SUBLOCADE is Powering Double-Digit Growth and Improved Mix
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 SUBLOCADE is Powering Double-Digit Growth and Improved Mix Total & SUBLOCADE Net Net Revenue Mix Revenue ($m) SUBLOCADE $1,285 4% All Other Products 24% $1,093 2% $435 $903 20% $791 $463 $1,124m $647 $495 $647m
Slide 91: Margin Expansion from Scalable Business Model
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Margin Expansion from Scalable Business Model Adj Op Profit ($m) & Margin % Scalable Business Model 45% $35 0 Reported $355 40% • Mix improvement driven by SUBLOCADE Adjusted1 35% • Leveraging growth investment
Slide 92: Acquired Manufacturing to Deliver Savings and Help Secure Supply
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Acquired Manufacturing to Deliver Savings and Help Secure Supply • Acquired multi-use, sterile manufacturing site in Raleigh, N.C. in November 2023 • Will enable in-house manufacturing of key strategic products
Slide 93: Strong Cash Generation to Fund Growth and Meet Obligations
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Strong Cash Generation to Fund Growth and Meet Obligations $35 0 Improving Adjusted EBITDA 1 Profile ($ in mil.) Gross Cash3 and Investments ($ in mil.) Reported $289 $1,102 Adjusted2 $991 $25 0 $235 $233 $209
Slide 94: Balanced Capital Allocation Framework
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Balanced Capital Allocation Framework Organic Growth and Business Needs • Growth investments to drive SUBLOCADE, PERSERIS Cash: Existing and Generated and launch OPVEE • Pipeline advancement and strengthening O
Slide 95: Leading to an Attractive Medium-Term Financial Profile
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Leading to an Attractive Medium-Term Financial Profile Attractive Positive Anticipated Growth Operating Strengthening Profile Leverage Cash Flow Expected double-digit % NR CAGR Gross margin mid-80%s Capital-lig
Slide 96: Q1 2024 Results & FY 2024 Outlook
Q1 2024 Results & FY 2024 Outlook
Slide 97: Q1 / FY 2024 Guidance
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Q1 / FY 2024 Guidance Q1 2024 Actuals FY 2024 Guidance1 ➤ Q1 2024 total NR growth of 12% (12% at constant FX) Total Net Revenue $1,240m to $1,330m (up 18% at mid-point) Key Products: ➤ Q1 2024 SUBLOCADE NR of $
Slide 98: U.S. Listing Update & Closing Remarks
U.S. Listing Update & Closing Remarks Mark Crossley CHIEF EXECUTIVE OFFICER
Slide 99: U.S. Primary Listing Update
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 U.S. Primary Listing Update Net Revenue by Geography Background & Context Expected Benefits Tentative Timeline • U.S. NR represents 84% of • Elevate profile as 16% addiction treatment Q4 Feb 22nd total NR (FY 2
Slide 100: Confident in our Ability to Transform Patient Lives and Create Durable Shareholder Value
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Confident in our Ability to Transform Patient Lives and Create Durable Shareholder Value We are a global leader in SUBLOCADE is a transformational addiction treatment asset with >$1.5 bn global opportunity1 We
Slide 101: Q&A
Q&A SG INDIVIOR
Slide 102: Appendix
Appendix SE INDIVIOR
Slide 103: Biographies
ANALYST TEACH-IN | MAY 23, 2024 Biographies Ma rk was appointed Chief Executive Officer in June 2020. Ma rk was appointed to the Board and as Chief Financial Operations in February 2017. In July 2019, Mark took on additional responsibilities and was appointed Chief Financial and Operations Officer i
Slide 104: Biographies
ANALYST TEACH-IN | MAY 23, 2024 Biographies Chri stian combines 30 years leadership experience in the neurosciences spanning the academic, governmental, and industrial sectors across Europe and the U.S. During his career, he a uthored and co-authored over 450 peer-reviewed scientific publications, r
Slide 105: Biographies
ANALYST TEACH-IN | MAY 23, 2024 Biographies Rya n was appointed Chief Financial Officer and Executive Director in November 2020, having served as Interim Financial Officer since June 2020. Ryan has been in a financial leadership ca pacity since joining Indivior in 2012 and prior to his appointment a
Slide 106: Our History & Major Milestones
T R A N SFO RMI N G L I VE S & D R I VI NG V A L U E C R E A TI O N | M A Y 2 3 , 2 0 2 4 Our History & Major Milestones Pre-2000 2000 - 2010 2010 - 2020 2020 - Current 1966 Reckitt & Colman (later renamed RB) 2000 DATA 2000 law passed in U.S. 2010 RB buys back remaining Global 2020 DOJ matter settl
Slide 107: Key SUBLOCADE KPIs – Last 5 years
ANALYST TEACH-IN | MAY 23, 2024 Key SUBLOCADE KPIs – Last 5 years Patients (K) Dispenses (K) WAC (Gross) Price Channel Mix 12-month rolling Excludes bulk orders 509.0 136.9 $1,920.50 $1,829.05 60% $1,741.95 65% 70% 316.2 75% 82.5 80% $1,659.00 $1,580.00 183.0 49.0 127.0 28.9 40% 59.0 35% 13.7 30% 25
Slide 108: Financial Reconciliations
ANALYST TEACH-IN | MAY 23, 2024 Financial Reconciliations 2023 2022 2021 2020 For the twelve months ended December 31 $m $m $m $m Gross profit 907 742 664 550 Exceptional items and other adjustments in cost of sales 8 — — 5 Adjusted gross profit 915 742 664 555 2023 2022 2021 2020 For the twelve mon
Slide 109: Indivior
3 < INDIVIOR’